MananaB.(Kvaratskhelia)EliaMD

Oncology • Duarte, CA

Hematology-Oncology, The University of Kansas Cancer Center

Join to view full profile

Dr. Elia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Elia's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 913-574-2413

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2002
University of Kansas Medical CenterNo degree, Breast Cancer Program, 2001
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
Emory University School of MedicineResidency, Internal Medicine, 1997 - 1999
Tbilisi State Medical InstitutePh.D., Post-Doctoral Fellowship (Hepatology), 1986 - 1990
Tbilisi State Medical UniversityClass of 1982

Certifications & Licensure

CA State Medical License 2022 - 2026
KS State Medical License 2000 - 2024
MO State Medical License 2002 - 2024
GA State Medical License 1999 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Summa Cum Laude Tbilisi State Medical Institute, 1982

Publications & Presentations

PubMed

11 citations
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
Shane R Stecklein, Bruce F Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M Staley
NPJ Breast Cancer. 2023-03-06
22 citations
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
Rachel Yoder, Bruce F Kimler, Joshua M Staley, Kelsey Schwensen, Yen Y Wang
NPJ Breast Cancer. 2022-07-11
34 citations
Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, Lauren Nye, Ingrid A. Mayer
Clinical Cancer Research. 2021-02-18

Journal Articles

Substantial Variation of NAP Estrone and Estradiol Levels Between Ducts in High Risk Women
Elia M., Breast Cancer Research and Treatment, 1/1/2002
Humoral and Cellular Immunity in Alcoholic Liver Disease
Elia M., Soviet Medical Journals
Familial Mediterranean Fever
Elia M., Soviet Medical Journals